Virus excretion and strain specific antibody responses after oral poliovaccine in previously immunised children
- PMID: 2828521
- DOI: 10.1002/jmv.1890230307
Virus excretion and strain specific antibody responses after oral poliovaccine in previously immunised children
Abstract
A nation-wide campaign with trivalent oral poliovirus vaccine was organized in Finland in February-March 1985 in order to stop the unexpected outbreak of poliomyelitis. Excretion time of the vaccine viruses and antibody responses due to vaccination were studied in a group of healthy 6-year-old children who were classmates to one of the patients during the outbreak and who also had been screened for excretion of the epidemic poliovirus type 3 strain. While faecal excretion of at least one of the three vaccine virus serotypes was documented in all 19 children, only one throat specimen out of 106 studied was positive in the virus isolation test. The mean excretion times for types 1, 2, and 3 were 13, 21, and 21 days, respectively, and five children were still excreting a vaccine virus strain at 5 wk. Faecal excretion of the type 3 vaccine virus was not seen in children who had been excreting the epidemic type 3 strain 4 mo earlier. Excretion of a respective vaccine virus strain was usually well correlated to a booster response in serum neutralising antibodies to types 2 and 3 but not to type 1 poliovirus. A relatively high prevaccination antibody level did not always prevent the take of the corresponding vaccine virus strain. An increase in the level of neutralising serum antibodies towards at least one poliovirus serotype was observed in all but one of the 17 children studied. Antibody responses to the live vaccine strains were similar to those towards the corresponding nonattenuated strains while the absolute antibody titres against the epidemic P3/Finland/23127/84 strain remained relatively low in most sera studied.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Antipolio prophylaxis of immunocompromised children during a nationwide oral poliovaccine campaign.Pediatr Infect Dis J. 1987 Dec;6(12):1106-10. Pediatr Infect Dis J. 1987. PMID: 2829105
-
The response to oral poliovaccine in persons aged 16-18 years.J Hyg (Lond). 1976 Apr;76(2):235-47. doi: 10.1017/s0022172400055133. J Hyg (Lond). 1976. PMID: 177700 Free PMC article.
-
Antibody response and viral excretion after live polio vaccine or a combined schedule of live and inactivated polio vaccines.Pediatr Infect Dis J. 1994 Dec;13(12):1117-21. doi: 10.1097/00006454-199412000-00009. Pediatr Infect Dis J. 1994. PMID: 7892081 Clinical Trial.
-
Global eradication of poliomyelitis: reinvent the wheel or use existing options effectively?Public Health Rev. 1993-1994;21(1-2):143-50. Public Health Rev. 1993. PMID: 8041881 Review.
-
Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review.Rev Infect Dis. 1991 Sep-Oct;13(5):926-39. doi: 10.1093/clinids/13.5.926. Rev Infect Dis. 1991. PMID: 1660184 Review.
Cited by
-
Cleavage of VP1 and modification of antigenic site 1 of type 2 polioviruses by intestinal trypsin.J Virol. 1988 Sep;62(9):3536-9. doi: 10.1128/JVI.62.9.3536-3539.1988. J Virol. 1988. PMID: 2841503 Free PMC article.
-
Radiometric cytolysis inhibition assay, a new rapid test for neutralizing antibodies to intact and trypsin-cleaved poliovirus.J Clin Microbiol. 1989 Apr;27(4):709-15. doi: 10.1128/jcm.27.4.709-715.1989. J Clin Microbiol. 1989. PMID: 2542364 Free PMC article.
-
Inadequacy of mucosal IgM antibodies in selective IgA deficiency: excretion of attenuated polio viruses is prolonged.J Clin Immunol. 1988 Mar;8(2):89-94. doi: 10.1007/BF00917895. J Clin Immunol. 1988. PMID: 2836474
-
Poliovirus vaccination options for achieving eradication and securing the endgame.Curr Opin Virol. 2013 Jun;3(3):309-15. doi: 10.1016/j.coviro.2013.05.007. Epub 2013 Jun 10. Curr Opin Virol. 2013. PMID: 23759252 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical